Viewing data from:

LISRAYA

NDA

BREPOCITINIB TOSYLATE | N220106 | PRIOVANT THERAPEUTICS INC

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Aug 28, 2026	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 30MG BASE

RLD

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Aug 27, 2026

No patent or exclusivity listings for this strength.

Change History (1)

Recent changes detected for this application.

ADDED10/19/2026

Lisraya (brepocitinib tosylate) gained new chemical entity exclusivity expiring Aug 2031.

New: LISRAYA (BREPOCITINIB TOSYLATE) — exclusivity NCE exp 08/27/2031